Tags

Type your tag names separated by a space and hit enter

High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study.
Arch Gerontol Geriatr. 2005 Nov-Dec; 41(3):239-53.AG

Abstract

We evaluated the efficacy and safety of high-dose pergolide treatment in patients with moderate to severe Parkinson's disease (PD) in an open-label multicenter clinical trial. The primary objective was to assess the amount of reduction in levodopa, the improvement in Unified Parkinson's Disease Rating Scale (UPDRS) and adverse reactions. We treated 32 patients with PD presenting with motor fluctuations. Pergolide treatment started with a dose escalation period of 12 weeks followed by a 12-week continuation period. Pergolide doses were increased up to a maximum of 12 mg/day in combination with a simultaneous decrease of levodopa doses in 100mg steps. Levodopa was reduced from 500 mg/day (median) to 250 mg/day. Mean UPDRS part III improved significantly (p=0.01). Clinical global impression improved significantly after 24 weeks (p<0.01). Most frequent adverse events were hallucinations, asthenia, anxiety, abdominal pain, and peripheral edema. Twenty-two patients finished the complete study according to protocol. A possible relationship to the study medication was assumed for two serious adverse events reporting psychosis. We conclude that high doses of pergolide are efficacious in advanced stages of PD if given in appropriate regimens.

Authors+Show Affiliations

Department of Neurology, Charité, University Hospital Berlin, Schumannstrasse 20/21, D-10117 Berlin, Germany. guy.arnold@charite.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Controlled Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16029905

Citation

Arnold, Guy, et al. "High Doses of Pergolide Improve Clinical Global Impression in Advanced Parkinson's Disease:- a Preliminary Open Label Study." Archives of Gerontology and Geriatrics, vol. 41, no. 3, 2005, pp. 239-53.
Arnold G, Gasser T, Storch A, et al. High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study. Arch Gerontol Geriatr. 2005;41(3):239-53.
Arnold, G., Gasser, T., Storch, A., Lipp, A., Kupsch, A., Hundemer, H. P., & Schwarz, J. (2005). High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study. Archives of Gerontology and Geriatrics, 41(3), 239-53.
Arnold G, et al. High Doses of Pergolide Improve Clinical Global Impression in Advanced Parkinson's Disease:- a Preliminary Open Label Study. Arch Gerontol Geriatr. 2005 Nov-Dec;41(3):239-53. PubMed PMID: 16029905.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study. AU - Arnold,Guy, AU - Gasser,Thomas, AU - Storch,Alexander, AU - Lipp,Axel, AU - Kupsch,Andreas, AU - Hundemer,Hans-Peter, AU - Schwarz,Johannes, Y1 - 2005/07/18/ PY - 2004/08/18/received PY - 2005/04/11/revised PY - 2005/04/14/accepted PY - 2005/7/21/pubmed PY - 2006/1/18/medline PY - 2005/7/21/entrez SP - 239 EP - 53 JF - Archives of gerontology and geriatrics JO - Arch Gerontol Geriatr VL - 41 IS - 3 N2 - We evaluated the efficacy and safety of high-dose pergolide treatment in patients with moderate to severe Parkinson's disease (PD) in an open-label multicenter clinical trial. The primary objective was to assess the amount of reduction in levodopa, the improvement in Unified Parkinson's Disease Rating Scale (UPDRS) and adverse reactions. We treated 32 patients with PD presenting with motor fluctuations. Pergolide treatment started with a dose escalation period of 12 weeks followed by a 12-week continuation period. Pergolide doses were increased up to a maximum of 12 mg/day in combination with a simultaneous decrease of levodopa doses in 100mg steps. Levodopa was reduced from 500 mg/day (median) to 250 mg/day. Mean UPDRS part III improved significantly (p=0.01). Clinical global impression improved significantly after 24 weeks (p<0.01). Most frequent adverse events were hallucinations, asthenia, anxiety, abdominal pain, and peripheral edema. Twenty-two patients finished the complete study according to protocol. A possible relationship to the study medication was assumed for two serious adverse events reporting psychosis. We conclude that high doses of pergolide are efficacious in advanced stages of PD if given in appropriate regimens. SN - 0167-4943 UR - https://www.unboundmedicine.com/medline/citation/16029905/High_doses_of_pergolide_improve_clinical_global_impression_in_advanced_Parkinson's_disease:__a_preliminary_open_label_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0167-4943(05)00038-5 DB - PRIME DP - Unbound Medicine ER -